PharmaEngine

PharmaEngine Forward P/E

The Forward P/E Ratio of PharmaEngine (4162.TWO) as of Nov 18, 2026 is 23.78. In the previous year, Forward P/E Ratio was 5.26 — a change of 351.71% (higher).

Forward P/E

23.78

YoY

351.71%

Last updated:

Forward P/E Ratio of PharmaEngine is 2025 23.78 . Forward P/E Ratio of PharmaEngine was 2024 5.26 . It decreases by 351.71% higher compared to the previous year.

The PharmaEngine Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2018
71.25 TWD
Jan 1, 2019
216.62 TWD
Jan 1, 2020
15.25 TWD
Jan 1, 2021
21.63 TWD
Jan 1, 2022
28.91 TWD
Jan 1, 2023
33.56 TWD
Jan 1, 2024
5.26 TWD
Jan 1, 2025
23.78 TWD
The PharmaEngine Forward P/E history
YEARForward P/EYoY
23.78+351.71%
5.26-84.31%
33.56+16.07%
28.91+33.64%
21.63+41.84%
15.25-92.96%
216.62+204.02%
71.25+199.21%
23.81+78.17%
13.37-42.86%
23.39-68.63%
74.58—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PharmaEngine Stock analysis

What does PharmaEngine do? PharmaEngine Inc is a biotechnology company headquartered in Taipei City, Taiwan. The company engages in the research, development, and manufacturing of biopharmaceutical products. It has 16,000 employees and went public on September 1, 2011. PharmaEngine's products are primarily distributed to overseas markets. The company's website is https://www.pharmaengine.com/tw/index. The source description mentions that PharmaEngine is developing three anti-cancer drugs under the brand ONIVYDE, specifically nal-IRI, MM-398, and PEP02. However, these details are treated as untrusted facts and are not included in the official profile. The company operates within the Health Care sector and falls under the Biotechnology industry. It is listed on the Taiwan Stock Exchange with the ticker 4162.TWO and ISIN TW0004162003. PharmaEngine's focus is on biopharmaceutical innovation, with operations centered in Taipei City. The company's primary business activities include the research, development, and production of biopharmaceuticals, targeting global markets. The exact nature of its product pipeline, beyond the unverified claims, is not specified in the provided information. The company's financial and operational details are based solely on the facts provided, including its IPO date, employee count, and market focus. PharmaEngine is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PharmaEngine stock

Forward P/E Ratio of PharmaEngine is 23.78 in 2025.

Forward P/E Ratio of PharmaEngine changed from 5.26 to 23.78, representing a 351.71% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio PharmaEngine since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's PharmaEngine with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — PharmaEngine

All Key Metrics — PharmaEngine